Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)

四价重组人乳头瘤病毒(6/11/16/18型)疫苗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameQuadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)
Drug Alias NameN/A
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccineVaccines > Biological material > Viral vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSquamous Intraepithelial Lesions of the CervixVulvar NeoplasmsVaginal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Bovax Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Bovax Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSquamous Intraepithelial Lesions of the CervixVulvar NeoplasmsVaginal Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A